Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy

Biomaterials

Volumn 51, Issue , 2015, Pages 22-29

  Alferiev, Ivan S ^a   Iyer, Radhika ^a   Croucher, Jamie L ^a   Adamo, Richard F ^a   Zhang, Kehan ^a   Mangino, Jennifer L ^a   Kolla, Venkatadri ^a   Fishbein, Ilia ^a   Brodeur, Garrett M ^a   Levy, Robert J ^a   Chorny, Michael ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Drug delivery; Nanoparticle; Neuroblastoma; Prodrug; Topoisomerase I inhibitor

Indexed keywords

CHEMICAL MODIFICATION; CONTROLLED DRUG DELIVERY; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; TUMORS;

ANTI-CANCER AGENTS; ANTI-TUMOR ACTIVITIES; ANTICANCER POTENTIALS; CLINICAL APPLICATION; NEUROBLASTOMA CELLS; NEUROBLASTOMAS; PRODRUGS; TOPOISOMERASE I;

TARGETED DRUG DELIVERY;

FIRTECAN; NANOCARRIER; PRODRUG; ALPHA TOCOPHEROL; CAMPTOTHECIN; IRINOTECAN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIODEGRADABILITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEGRADATION; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; MITOSIS RATE; MOUSE; NANOENCAPSULATION; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; NUDE MOUSE; PARTICLE SIZE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALIA;

ALPHA-TOCOPHEROL; ANIMALS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; HUMANS; MICE, NUDE; NANOPARTICLES; NEUROBLASTOMA; PARTICLE SIZE; PRODRUGS; TREATMENT OUTCOME;

EID: 84924911597     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.01.075     Document Type: Article

References (52)

1. McNeil S.E. Unique benefits of nanotechnology to drug delivery and diagnostics. Methods Mol Biol 2011, 697:3-8.
2. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. JControl Release 2012, 161(2):175-187.
3. Florence A.T. "Targeting" nanoparticles: the constraints of physical laws and physical barriers. JControl Release 2012, 164(2):115-124.
4. Nichols J.W., Bae Y.H. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today 2012, 7(6):606-618.
5. Crist R.M., Grossman J.H., Patri A.K., Stern S.T., Dobrovolskaia M.A., Adiseshaiah P.P., et al. Common pitfalls in nanotechnology: lessons learned from NCI's nanotechnology characterization laboratory. Integr Biol Camb 2012, 5(1):66-73.
6. Washington C. Drug release from microdisperse systems: a critical review. Int J Pharm 1990, 58:1-12.
7. Zou P., Helson L., Maitra A., Stern S.T., McNeil S.E. Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm 2013, 10(5):1977-1987.
8. Letchford K., Burt H.M. Copolymer micelles and nanospheres with different invitro stability demonstrate similar paclitaxel pharmacokinetics. Mol Pharm 2012, 9(2):248-260.
9. Miller T., Breyer S., van Colen G., Mier W., Haberkorn U., Geissler S., et al. Premature drug release of polymeric micelles and its effects on tumor targeting. Int J Pharm 2013, 445(1-2):117-124.
10. Sun Q., Radosz M., Shen Y. Challenges in design of translational nanocarriers. JControl Release 2012, 164(2):156-169.
11. Xiong M.P., Yanez J.A., Remsberg C.M., Ohgami Y., Kwon G.S., Davies N.M., et al. Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. JControl Release 2008, 129(1):33-40.
12. Zhao Y., Duan S., Zeng X., Liu C., Davies N.M., Li B., et al. Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm 2012, 9(6):1705-1716.
13. Forrest M.L., Yanez J.A., Remsberg C.M., Ohgami Y., Kwon G.S., Davies N.M. Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res 2008, 25(1):194-206.
14. Lundberg B.B. Preparation and characterization of polymeric pH-sensitive STEALTH(R) nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel. Int J Pharm 2011, 408(1-2):208-212.
15. Bomgaars L., Berg S.L., Blaney S.M. The development of camptothecin analogs in childhood cancers. Oncologist 2001, 6(6):506-516.
16. Venditto V.J., Simanek E.E. Cancer therapies utilizing the camptothecins: a review of the invivo literature. Mol Pharm 2010, 7(2):307-349.
17. Kieler-Ferguson H.M., Frechet J.M., Szoka F.C. Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2013, 5(2):130-138.
18. Férriz J.M., Vinšová J. Prodrug design of phenolic drugs. Curr Pharm Des 2010, 16(18):2033-2052.
19. Testa B., Mayer J.M. The hydrolysis of carboxylic acid ester prodrugs. Hydrolysis in drug and prodrug metabolism: chemistry, biochemistry, and enzymology 2006, 419-534. Verlag Helvetica Chimica Acta, Zürich, Switzerland.
20. Perrault S.D., Walkey C., Jennings T., Fischer H.C., Chan W.C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 2009, 9(5):1909-1915.
21. Fishbein I., Chorny M., Banai S., Levitzki A., Danenberg H.D., Gao J., et al. Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc Biol 2001, 21(9):1434-1439.
22. Zhao H., Rubio B., Sapra P., Wu D., Reddy P., Sai P., et al. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug Chem 2008, 19(4):849-859.
23. Chorny M., Fishbein I., Danenberg H.D., Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. JControl Release 2002, 83(3):389-400.
24. Tengood J.E., Alferiev I.S., Zhang K., Fishbein I., Levy R.J., Chorny M. Real-time analysis of composite magnetic nanoparticle disassembly in vascular cells and biomimetic media. Proc Natl Acad Sci U S A 2014, 111(11):4245-4250.
25. Patterson D.M., Shohet J.M., Kim E.S. Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery. Curr Protoc Pharmacol 2011, 52:14.17.1-14.17.18. [Chapter 14].
26. Thompson J.F., Hayes L.S., Lloyd D.B. Modulation of firefly luciferase stability and impact on studies of gene regulation. Gene 1991, 103(2):171-177.
27. Ho R., Eggert A., Hishiki T., Minturn J.E., Ikegaki N., Foster P., et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002, 62(22):6462-6466.
28. Moriguchi I., Hirono S., Liu Q., Nakagome I., Matsushita Y. Simple method of calculating octanol/water partition coefficient. Chem Pharm Bull 1992, 40(1):127-130.
29. ® - the first FDA-approved nano-drug: lessons learned. JControl Release 2012, 160(2):117-134.
30. Brown D.C., Gatter K.C. Ki67 protein: the immaculate deception?. Histopathology 2002, 40(1):2-11.
31. McNeil S.E. Challenges for nanoparticle characterization. Methods Mol Biol 2011, 697:9-15.
32. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., et al. Formulation of functionalized PLGA-PEG nanoparticles for invivo targeted drug delivery. Biomaterials 2007, 28(5):869-876.
33. Debotton N., Parnes M., Kadouche J., Benita S. Overcoming the formulation obstacles towards targeted chemotherapy: invitro and invivo evaluation of cytotoxic drug loaded immunonanoparticles. JControl Release 2008, 127(3):219-230.
34. Atyabi F., Farkhondehfai A., Esmaeili F., Dinarvand R. Preparation of pegylated nano-liposomal formulation containing SN-38: Invitro characterization and invivo biodistribution in mice. Acta Pharm 2009, 59(2):133-144.
35. Bala V., Rao S., Boyd B.J., Prestidge C.A. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. JControl Release 2013, 172(1):48-61.
36. Vangara K.K., Ali H.I., Lu D., Liu J.L., Kolluru S., Palakurthi S. SN-38-cyclodextrin complexation and its influence on the solubility, stability, and invitro anticancer activity against ovarian cancer. AAPS PharmSciTech 2014, 15(2):472-482.
37. Garcia-Carbonero R., Supko J.G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002, 8(3):641-661.
38. Mathijssen R.H., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001, 7(8):2182-2194.
39. Slatter J.G., Schaaf L.J., Sams J.P., Feenstra K.L., Johnson M.G., Bombardt P.A., et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000, 28(4):423-433.
40. Pietzonka P., Rothen-Rutishauser B., Langguth P., Wunderli-Allenspach H., Walter E., Merkle H.P. Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to caco-2 monolayers mimics particle uptake. Pharm Res 2002, 19(5):595-601.
41. Xu P., Gullotti E., Tong L., Highley C.B., Errabelli D.R., Hasan T., et al. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm 2009, 6(1):190-201.
42. Hofmann D., Messerschmidt C., Bannwarth M.B., Landfester K., Mailander V. Drug delivery without nanoparticle uptake: delivery by a kiss-and-run mechanism on the cell membrane. Chem Commun Camb 2013, 50(11):1369-1371.
43. Constantinides P.P., Han J., Davis S.S. Advances in the use of tocols as drug delivery vehicles. Pharm Res 2006, 23(2):243-255.
44. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006, 6(10):789-802.
45. Pastorino F., Loi M., Sapra P., Becherini P., Cilli M., Emionite L., et al. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res 2010, 16(19):4809-4821.
46. Zhao Y., Neuzil J., Wu K. Vitamin E analogues as mitochondria-targeting compounds: from the bench to the bedside?. Mol Nutr Food Res 2009, 53(1):129-139.
47. Duhem N., Danhier F., Préat V. Vitamin E-based nanomedicines for anti-cancer drug delivery. JControl Release 2014, 182:33-44.
48. Prasad K.N., Kumar B., Yan X.D., Hanson A.J., Cole W.C. Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. JAm Coll Nutr 2003, 22(2):108-117.
49. Swettenham E., Witting P.K., Salvatore B.A., Neuzil J. Alpha-tocopheryl succinate selectively induces apoptosis in neuroblastoma cells: potential therapy of malignancies of the nervous system?. JNeurochem 2005, 94(5):1448-1456.
50. Prasad K.N., Cohrs R.J., Sharma O.K. Decreased expressions of c-myc and H-ras oncogenes in vitamin E succinate induced morphologically differentiated murine B-16 melanoma cells in culture. Biochem Cell Biol 1990, 68(11):1250-1255.
51. You H., Yu W., Sanders B.G., Kline K. RRR-alpha-tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation. Cell Growth Differ 2001, 12(9):471-480.
52. Prasad K.N., Kentroti S., Edwards-Prasad J., Vernadakis A., Imam M., Carvalho E., et al. Modification of the expression of adenosine 3',5'-cyclic monophosphate-induced differentiated functions in neuroblastoma cells by beta-carotene and D-alpha-tocopheryl succinate. JAm Coll Nutr 1994, 13(3):298-303.